Nama Insights

Innoviva (INVA)

Healthcare · Biotechnology · NASDAQ

Innoviva (INVA) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.31B, a trailing price-to-earnings ratio of 39.2 and a free-cash-flow yield of 11.9%. Over the most recent reported fiscal year, revenue grew 14.7% and free cash flow per share fell 11.5%. Nama's AI scorecard rates it Buy, 8.2 out of 10. On 12-month momentum it ranks in the lagging band of its market.
AI scorecard
Buy · 8.2/10
Clearly positive, short of the top band. As of Nov 20, 2026.
Momentum
Lagging · -1.2% over 12 months ex. last
Second-worst fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-26.8%
How far the last close sits under the highest price of the past five years.
Market cap$1.31B
Trailing P/E39.2
Price / book1.2
Price / sales3.0
FCF yield11.9%
Dividend yield—
Gross margin82.0%
Operating margin38.8%
Net margin44.1%
Revenue growth (YoY)+14.7%
Revenue growth (3-yr annual)+7.5%
EPS growth (YoY)—
FCF/share growth (YoY)-11.5%
Beta0.4
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology

INVA earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate $0.45). Beat the EPS estimate in 3 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 4, 2026 -$1.03 $0.34 -402.9% $106.12M
Q2 2026 Aug 5, 2026 $0.56 $0.50 +12.0% $119.59M
Q1 2026 May 6, 2026 $0.47 $0.43 +9.3% $97.99M
Q4 2025 Feb 25, 2026 $0.47 $0.43 +9.3% $114.61M

INVA analyst price target

Median target $34.00 from 6 analysts, ranging $18.00 – $46.00.

Biotechnology peers

TickerCompanyMarket capP/E
VRTX Vertex Pharmaceuticals $132.01B 27.4
REGN Regeneron Pharmaceuticals $95.52B 16.7
MRNA Moderna $80.65B —
ARGX argenx $59.24B 32.9
ONC BeOne Medicines $45.66B 50.8
RPRX Royalty Pharma $38.94B 12.8
RVMD Revolution Medicines $34.48B —
INSM Insmed $31.69B —
Explore live INVA data on Nama Insights →

Recent Congressional trades

Innoviva trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member Chamber Trade Amount Disclosed
George Whitesides House Sell $250,001 - $500,000 Apr 23, 2025
George Whitesides House Sell $50,001 - $100,000 Apr 23, 2025

INVA FAQ

Is INVA a buy?
Nama's AI scorecard currently rates Innoviva Buy (8.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is INVA's P/E ratio?
Innoviva trades at a trailing price-to-earnings ratio of 39.2.
When does INVA report earnings?
Innoviva's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.45.
What is the INVA price target?
The median analyst price target from 6 analysts is $34.00, with a range of $18.00 – $46.00.
Is INVA Shariah compliant?
Nama's AAOIFI-style screen reads Innoviva as Not Shariah Compliant. At least one of the three ratios or the industry test failed.